Randomized, double blind, placebo controlled trial
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 (3rd June)
BACKGROUND
Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.
METHODS
Randomized, double-blind, placebo-controlled trial
United States and Canada
Testing hydroxychloroquine as postexposure prophylaxis
High risk, less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield
Moderate risk, while wearing a face mask but no eye shield
n = 821 asymptomatic participants (719 of 821) reported a high-risk exposure
Randomly assigned, placebo or hydroxychloroquine groups within 4 days of exposure
Primary outcome, incidence positive test of clinical diagnosis
RESULTS
Incidence of new illness
Hydroxychloroquine group (49 of 414), 11.8%
Placebo group (58 of 407), 14.3%
P=0.35
Side effects in hydroxychloroquine group = 40.1%
Side effects in control group = 16.8%
No serious adverse reactions were reported.
(Nausea, upset stomach, dizziness, headache)
Hydroxychloroquine group
Taking zinc 15% developed new disease
Not taking zinc 10.8% developed new disease
Placebo group
Taking zinc 15.4% developed new disease
Not taking zinc 14% developed new disease
Relative risk with zinc use was 1.23
Hydroxychloroquine group
Taking Vit C 14.3% developed new disease
Not taking Vit C 10.6% developed new disease
Placebo group
Taking Vit C 20.8% developed new disease
Not taking Vit C 11.2% developed new disease
Relative risk with vitamin C use was 1.60
The Lancet (and NEJM)
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, (May 22nd)
Serious scientific questions about the validity of data
‘Expression of Concern’
https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)31290-3/fulltext
Issued a correction regarding location of some patients
Conclusions were not changed.
WHO resumed its trial of hydroxychloroquine
Crisis of trust
Medical journals
WHO
Governments
Scientific / medical advisors
Видео Randomized, double blind, placebo controlled trial канала Dr. John Campbell
BACKGROUND
Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.
METHODS
Randomized, double-blind, placebo-controlled trial
United States and Canada
Testing hydroxychloroquine as postexposure prophylaxis
High risk, less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield
Moderate risk, while wearing a face mask but no eye shield
n = 821 asymptomatic participants (719 of 821) reported a high-risk exposure
Randomly assigned, placebo or hydroxychloroquine groups within 4 days of exposure
Primary outcome, incidence positive test of clinical diagnosis
RESULTS
Incidence of new illness
Hydroxychloroquine group (49 of 414), 11.8%
Placebo group (58 of 407), 14.3%
P=0.35
Side effects in hydroxychloroquine group = 40.1%
Side effects in control group = 16.8%
No serious adverse reactions were reported.
(Nausea, upset stomach, dizziness, headache)
Hydroxychloroquine group
Taking zinc 15% developed new disease
Not taking zinc 10.8% developed new disease
Placebo group
Taking zinc 15.4% developed new disease
Not taking zinc 14% developed new disease
Relative risk with zinc use was 1.23
Hydroxychloroquine group
Taking Vit C 14.3% developed new disease
Not taking Vit C 10.6% developed new disease
Placebo group
Taking Vit C 20.8% developed new disease
Not taking Vit C 11.2% developed new disease
Relative risk with vitamin C use was 1.60
The Lancet (and NEJM)
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, (May 22nd)
Serious scientific questions about the validity of data
‘Expression of Concern’
https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)31290-3/fulltext
Issued a correction regarding location of some patients
Conclusions were not changed.
WHO resumed its trial of hydroxychloroquine
Crisis of trust
Medical journals
WHO
Governments
Scientific / medical advisors
Видео Randomized, double blind, placebo controlled trial канала Dr. John Campbell
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Update for Wednesday](https://i.ytimg.com/vi/2CWsJTTHXBA/default.jpg)
![Vitamin D dose](https://i.ytimg.com/vi/Bga_qG30JyY/default.jpg)
![New evidence](https://i.ytimg.com/vi/e3lx6Scwfhg/default.jpg)
![Data on reinfections](https://i.ytimg.com/vi/gGllOW3zo1k/default.jpg)
![Oxygen in the blood](https://i.ytimg.com/vi/YyMiSUfZtyU/default.jpg)
![Hydroxychloroquine, evidence of efficacy](https://i.ytimg.com/vi/2uzXHnUViro/default.jpg)
![Pandemic Science, Reinfections and hydroxychloroquine](https://i.ytimg.com/vi/SBn4e69tGlg/default.jpg)
![How NOT to Conduct a Randomized Clinical Trial](https://i.ytimg.com/vi/PRCQ-kIxQyY/default.jpg)
![Vitamin D and immunity](https://i.ytimg.com/vi/W5yVGmfivAk/default.jpg)
![Scientific evidence for mask wearing](https://i.ytimg.com/vi/zhQw7vLNsDA/default.jpg)
![Best Upcoming Interior Design Trends](https://i.ytimg.com/vi/ibn8jYczi-k/default.jpg)
![Distance, masks and eye protection](https://i.ytimg.com/vi/2vT9BV8-0TA/default.jpg)
![Dr. Shelton, Prevention better than cure](https://i.ytimg.com/vi/RbZyOZIUFrU/default.jpg)
![COVID-19 Insights: Rapid Death due to SARS-COV (cytokine storm/massive immunomodulation)](https://i.ytimg.com/vi/8xAcQwrb6iE/default.jpg)
![Explaining Randomization in Clinical Trials](https://i.ytimg.com/vi/MmpF1zxfQZ8/default.jpg)
![Vitamin D, Science](https://i.ytimg.com/vi/cv4iINxf4IM/default.jpg)
![Delta pandemic](https://i.ytimg.com/vi/QXH3Vr2cXPc/default.jpg)
![Coronavirus, Dr Pravin Nair, Consultant Microbiologist](https://i.ytimg.com/vi/GUkZg7VH_tI/default.jpg)
![Friday 24th April, Global Update](https://i.ytimg.com/vi/ypsUIh41xUw/default.jpg)
![Delta goes to Europe](https://i.ytimg.com/vi/JETqBIl4mOo/default.jpg)